Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond

Clinical and Experimental Immunology

Volumn 136, Issue 1, 2004, Pages 1-10

  Simmonds, M J ^a   Gough, S C L ^a,b,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Autoimmune thyroid disease; CTLA 4 gene; HLA

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN; THYROGLOBULIN;

CHROMOSOME 8Q; DISEASE MODEL; DNA DETERMINATION; ENVIRONMENTAL FACTOR; GENE LOCUS; GENE MAPPING; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; GRAVES DISEASE; HASHIMOTO DISEASE; HEREDITY; HLA SYSTEM; HUMAN; HYPOTHYROIDISM; POPULATION RISK; PRIORITY JOURNAL; REVIEW; TG GENE; THYROID DISEASE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, DIFFERENTIATION; AUTOIMMUNE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; THYROID DISEASES;

EID: 1842455656     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02424.x     Document Type: Review

References (103)

1. Tunbridge WM, Evered DC, Hall R et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 1977; 7:481-93.
2. Gough SC. The genetics of Graves' disease. Endocrinol Metab Clin North Am 2000; 29:255-66.
3. Tait K, Marshall T, Berman J et al. Clustering of autoimmune disease in parents of siblings from type 1 diabetes Warren Repository. Diabetic Medicine 2004; 00:000-000. in press.
4. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138-46.
5. Bluher M, Krohn K, Wallaschofski H, Braverman LE, Paschke R. Cytokine gene expression in autoimmune thyroiditis in BioBreeding/Worcester rats. Thyroid 1999; 9:1049-55.
6. Ruwhof C, Drexhage HA. Iodine and thyroid autoimmune disease in animal models. Thyroid 2001; 11:427-36.
7. Voorby HA, Kabel PJ, de Haan M, Jeucken PH, van der Gaag RD, de Baets MH, Drexhage HA. Dendritic cells and class II MHC expression on thyrocytes during the autoimmune thyroid disease of the BB rat. Clin Immunol Immunopathol 1990; 55:9-22.
8. Roura-Mir C, Catalfamo M, Sospedra M, Alcalde L, Pujol-Borrell R, Jaraquemada D. Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' disease. Eur J Immunol 1997; 27:3290-302.
9. Bretz JD, Arscott PL, Myc A, Baker JR Jr. Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells. J Biol Chem 1999; 274:25433-8.
10. Stassi G, Di Liberto D, Todaro M et al. Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol 2000; 1:483-8.
11. Bartels ED. Twin examinations/Heredity in Graves' disease. Einar Copenhagen: Munksgaard, 1941:33-6 (Thesis).
12. Harvald B, Hauge M. Catamnestic investigation of Danish twins; a preliminary report. Dan Med Bull 1956; 3:150-8.
13. Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves' disease, a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001; 86:930-4.
14. Brix TH, Kyvik KO, Hegedus L. A population-based study of chronic autoimmune hypothyroidism in Danish twins. J Clin Endocrinol Metab 2000; 85:536-9.
15. Valtonen VV, Ruutu P, Vans K, Ranki M, Malkamaki M, Makela P. Serological evidence for the role of bacterial infections in the pathogenesis of thyroid diseases. Acta Med Scand 1986; 219:105-11.
16. Jaspan JB, Sullivan K, Garry RF et al. The interaction of a type A retroviral particle and class II human leukocyte antigen susceptibility genes in the pathogenesis of Graves' disease. J Clin Endocrinol Metab 1996; 81:2271-9.
17. Kung AW. Life events, daily stresses and coping in patients with Graves' disease. Clin Endocrinol 1995; 42:303-8.
18. Brucker-Davis F. Effects of environmental synthetic chemicals on thyroid function. Thyroid 1998; 8:827-56.
19. McIver B, Morris JC. The pathogenesis of Graves' disease. Endocrinol Metab Clin North Am 1998; 27:73-89.
20. Todd JA. Genetic analysis of type 1 diabetes using whole genome approaches. Proc Natl Acad Sci USA 1995; 92:8560-5.
21. Allahabadia A, Gough SC. The different approaches to the genetic analysis of autoimmune thyroid disease. J Endocrinol 1999; 163:7-13.
22. Vaidya B, Imrie H, Perros P et al. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Hum Mol Genet 1999; 8:1195-9.
23. Nithiyananthan R, Gough SC. Genetics of Graves' disease. In: Dutton J, Haik B, eds. Thyroid eye disease. New York: Marcel Dekker, 2002:113-25.
24. Grumet FC, Payne RO, Konishi J, Kriss JP. HL-A antigens as markers for disease susceptibility and autoimmunity in Graves' disease. J Clin Endocrinol Metab 1974; 39:1115-9.
25. Farid NR, Barnard JM, Marshall WH. The association of HLA with autoimmune thyroid disease in Newfoundland. The influence of HLA homozygosity in Graves' disease. Tissue Antigens 1976; 8:181-9.
26. Mather BA, Roberts DF, Scanlon MF, Mukhtar ED, Davies TF, Smith BR, Hall R. HLA antigens and thyroid autoantibodies in patients with Graves' disease and their first degree relatives. Clin Endocrinol 1980; 12:155-63.
27. Bech K, Lumholtz B, Nerup J etal. HLA antigens in Graves' disease. Acta Endocrinol 1977; 86:510-6.
28. Farid NR, Sampson L, Noel EP, Barnard JM, Mandeville R, Larsen B, Marshall WH, Carter ND. A study of human leukocyte D locus related antigens in Graves' disease. J Clin Invest 1979; 63:108-13.
29. Allanic H, Fauchet R, Lorcy Y, Heim J, Gueguen M, Leguerrier AM, Genetet B. Graves' disease. Predominance of the DRw3 antigen (author's transl). Nouv Presse Med 1980; 9:1823-6.
30. Dahlberg PA, Holmlund G, Karlsson FA, Safwenberg J. HLA-A-B-C and - DR antigens in patients with Graves' disease and their correlation with signs and clinical course. Acta Endocrinol 1981; 97:42-7.
31. Boehm BO, Kuhnl P, Manfras BJ etal. HLA-DRB3 gene alleles in Caucasian patients with Graves' disease. Clin Invest 1992; 70:956-60.
32. Ito M, Tanimoto M, Kamura H etal. Association of HLA antigen and restriction fragment length polymorphism of T cell receptor beta-chain gene with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1989; 69:100-4.
33. Yanagawa T, Mangklabruks A, Chang YB, Okamoto Y, Fisfalen ME, Curran PG, DeGroot LJ. Human histocompatibility leukocyte antigen-DQA1*0501 allele associated with genetic susceptibility to Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1993; 76:1569-74.
34. Barlow AB, Wheatcroft N, Watson P, Weetman AP. Association of HLA-DQA1*0501 with Graves' disease in English Caucasian men and women. Clin Endocrinol 1996; 44:73-7.
35. Cuddihy RM, Bahn RS. Lack of an independent association between the human leukocyte antigen allele DQA1*0501 and Graves' disease. J Clin Endocrinol Metab 1996; 81:847-9.
36. Hunt PJ, Marshall SE, Weetman AP, Bunce M, Bell JI, Wass JA, Welsh KI. Histocompatibility leucocyte antigens and closely linked immunomodulatory genes in autoimmune thyroid disease. Clin Endocrinol 2001; 55:491-9.
37. Maciel LM, Rodrigues SS, Dibbern RS, Navarro PA, Donadi EA. Association of the HLA-DRB1*0301 and HLA-DQA1*0501 alleles with Graves' disease in a population representing the gene contribution from several ethnic backgrounds. Thyroid 2001; 11:31-5.
38. Yanagawa T, Mangklabruks A, DeGroot LJ. Strong association between HLA-DQA1*0501 and Graves' disease in a male Caucasian population. J Clin Endocrinol Metab 1994; 79:227-9.
39. Heward JM, Allahabadia A, Daykin J etal. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. J Clin Endocrinol Metab 1998; 83:3394-7.
40. Moens H, Farid NR, Sampson L, Noel EP, Barnard JM. Hashimoto's thyroiditis is associated with HLA-DRw3. N Engl J Med 1978; 299:133-4.
41. Tandon N, Zhang L, Weetman AP. HLA associations with Hashimoto's thyroiditis. Clin Endocrinol 1991; 34:383-6.
42. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989; 7:445-80.
43. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13.
44. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3:611-8.
45. Marron MP, Zeidler A, Raffel LJ etal. Genetic and physical mapping of a type 1 diabetes susceptibility gene (IDDM12) to a 100-kb phagemid artificial chromosome clone containing D2S72-CTLA4-D2S105 on chromosome 2q33. Diabetes 2000; 49:492-9.
46. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995; 80:41-5.
47. Nistico L, Buzzetti R, Pritchard LE etal. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 1996; 5:1075-80.
48. Heward JM, Allahabadia A, Armitage M et al. The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 1999; 84:2398-401.
49. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000; 165:6606-11.
50. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183:2533-40.
51. Ueda H, Howson JM, Esposito L et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506-11.
52. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999; 29:3596-602.
53. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164:5015-8.
54. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000; 201:144-53.
55. Finger EB, Bluestone JA. When ligand becomes receptor - tolerance via B7 signaling on DCs. Nat Immunol 2002; 3:1056-7.
56. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996; 184:387-96.
57. Manzotti CN, Tipping H, Perry LC, Mead KI, Blair PJ, Zheng Y, Sansom DM. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol 2002; 32:2888-96.
58. Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F. CD4+CD25+ T (R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003; 197:111-9.
59. Sakaguchi S. Control of immune responses by naturally arising CD4+ regulatory T cells that express toll-like receptors. J Exp Med 2003; 197:397-401.
60. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-6.
61. Grohmann U, Orabona C, Fallarino F etal. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3:1097-101.
62. Lin H, Rathmell JC, Gray GS, Thompson CB, Leiden JM, Alegre ML. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice. CTLA4 can function independently of CD28. J Exp Med 1998; 188:199-204.
63. Cuddihy RM, Dutton CM, Bahn RS. A polymorphism in the extracellular domain of the thyrotropin receptor is highly associated with autoimmune thyroid disease in females. Thyroid 1995; 5:89-95.
64. Allahabadia A, Heward JM, Mijovic C etal. Lack of association between polymorphism of the thyrotropin receptor gene and Graves' disease in United Kingdom and Hong Kong Chinese patients: case control and family-based studies. Thyroid 1998; 8:777-80.
65. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA, Welsh K. I. Association of Graves' disease with an allele of the interleukin-1 receptor antagonist gene. J Clin Endocrinol Metab 2000; 80:111-5.
66. Heward JM, Nithiyananthan R, Allahabadia A, Gibson S, Franklyn JA, Gough SC. No association of an interleukin 4 gene promoter polymorphism with Graves' disease in the United Kingdom. J Clin Endocrinol Metab 2001; 86:3861-3.
67. Blakemore AI, Watson PF, Weetman AP, Duff GW. Association of Graves' disease with an allele of the interleukin-1 receptor antagonist gene. J Clin Endocrinol Metab 1995; 80:111-5.
68. Heward J, Allahabadia A, Gordon C, Sheppard MC, Barnett AH, Franklyn JA, Gough SC. The interleukin-1 receptor antagonist gene shows no allelic association with three autoimmune diseases. Thyroid 1999; 9:627-8.
69. Heward JM, Allahabadia A, Sheppard MC, Barnett AH, Franklyn JA, Gough SC. Association of the large multifunctional proteasome (LMP2) gene with Graves' disease is a result of linkage disequilibrium with the HLA haplotype DRB1*0304-DQB1*02-DQA1*0501. Clin Endocrinol 1999; 51:115-8.
70. Nithiyananthan R, Heward JM, Allahabadia A, Barnett AH, Franklyn JA, Gough SC. A heterozygous deletion of the autoimmune regulator (AIRE1) gene, autoimmune thyroid disease, and type 1 diabetes: no evidence for association. J Clin Endocrinol Metab 2000; 85:1320-2.
71. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29:306-9.
72. Tomer Y, Barbesino G, Greenberg DA, Concepcion E, Davies TF. Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: evidence for genetic heterogeneity and gene interactions. J Clin Endocrinol Metab 1999; 84:4656-64.
73. Tomer Y, Ban Y, Concepcion E, Barbesino G, Villanueva R, Greenberg DA, Davies TF. Common and unique susceptibility Loci in graves and hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am J Hum Genet 2003; 73:736-47.
74. Imrie H, Vaidya B, Perros P, Kelly WF, Toft AD, Young ET, Kendall-Taylor P, Pearce SH. Evidence for a Graves' disease susceptibility locus at chromosome Xp11 in a United Kingdom population. J Clin Endocrinol Metab 2001; 86:626-30.
75. Ban Y, Davies TF, Greenberg DA, Concepcion ES, Tomer Y. The influence of human leucocyte antigen (HLA) genes on autoimmune thyroid disease (AITD): results of studies in HLA-DR3 positive AITD families. Clin Endocrinol 2002; 57:81-8.
76. Sakai K, Shirasawa S, Ishikawa N etal. dentification of susceptibility loci for autoimmune thyroid disease to 5q31-q33 and Hashimoto's thyroiditis to 8q23-q24 by multipoint affected sib-pair linkage analysis in Japanese. Hum Mol Genet 2001; 10:1379-86.
77. Tomer Y, Greenberg DA, Concepcion E, Ban Y, Davies TF. Thyroglobulin is a thyroid specific gene for the familial autoimmune thyroid diseases. J Clin Endocrinol Metab 2002; 87:404-7.
78. Tomer Y. Anti-thyroglobulin autoantibodies in autoimmune thyroid diseases: cross-reactive or pathogenic? Clin Immunol Immunopathol 1997; 82:3-11.
79. Baas F, van Ommen GJ, Bikker H, Arnberg AC, de Vijlder JJ. The human thyroglobulin gene is over 300 kb long and contains introns of up to 64 kb. Nucl Acids Res 1986; 14:5171-86.
80. van de Graaf SA, Ris-Stalpers C, Pauws E, Mendive FM, Targovnik HM, de Vijlder JJ. Up to date with human thyroglobulin. J Endocrinol 2001; 170:307-21.
81. Collins JE, Heward JM, Carr-Smith J, Daykin J, Franklyn JA, Gough SC. Association of a rare thyroglobulin gene microsatellite variant with autoimmune thyroid disease. J Clin Endocrinol Metab 2003; 88:5039-42.
82. Ban Y, Greenberg DA, Concepcion E, Skrabanek L, Villanueva R, Tomer Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proceedings of the Natl Acad Sci USA 2003.
83. Concannon P, Gogolin-Ewens KJ, Hinds DA et al. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 1998; 19:292-6.
84. McPherson JD, Marra M, Hillier L et al. A physical map of the human genome. Nature 2001; 409:934-41.
85. Mangklabruks A, Cox N, DeGroot LJ. Genetic factors in autoimmune thyroid disease analyzed by restriction fragment length polymorphisms of candidate genes. J Clin Endocrinol Metab 1991; 73:236-44.
86. Badenhoop K, Schwarz G, Schleusener H, Weetman AP, Recks S, Peters H, Bottazzo GF, Usadel KH. Tumor necrosis factor beta gene polymorphisms in Graves' disease. J Clin Endocrinol Metab 1992; 74:287-91.
87. Badenhoop K, Walfish PG, Rau H, Fischer S, Nicolay A, Bogner U, Schleusener H, Usadel KH. Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J Clin Endocrinol Metab 1995; 80:2112-7.
88. Philippou G, Krimitzas A, Kaltsas G, Anastasiou E, Souvatzoglou A, Alevizaki M. HLA DQA1*0501 and DRB1*0301 antigens do not independently convey susceptibility to Graves' disease. J Endocrinol Invest 2001; 24:88-91.
89. Weissel M, Hofer R, Zasmeta H, Mayr WR. HLA-DR and Hashimoto's thyroiditis. Tissue Antigens 1980; 16:256-7.
90. Jenkins D, Penny MA, Fletcher JA, Jacobs KH, Mijovic CH, Franklyn JA, Sheppard MC. HLA class II gene polymorphism contributes little to Hashimoto's thyroiditis. Clin Endocrinol 1992; 37:141-5.
91. Wan XL, Kimura A, Dong RP, Honda K, Tamai H, Sasazuki T. HLA-A and -DRB4 genes in controlling the susceptibility to Hashimoto's thyroiditis. Hum Immunol 1995; 42:131-6.
92. Petrone A, Giorgi G, Mesturino CA etal. Association of DRB1*04-DQB1*0301 haplotype and lack of association of two polymorphic sites at CTLA-4 gene with Hashimoto's thyroiditis in an Italian population. Thyroid 2001; 11:171-5.
93. Kotsa K, Watson PF, Weetman AP. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol 1997; 46:551-4.
94. Donner H, Rau H, Walfish PG et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 1997; 82:143-6.
95. Donner H, Braun J, Seidl C etal. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab 1997; 82:4130-2.
96. Djilali-Saiah I, Larger E, Harfouch-Hammoud E etal. No major role for the CTLA-4 gene in the association of autoimmune thyroid disease with IDDM. Diabetes 1998; 47:125-7.
97. Buzzetti R, Nistico L, Signore A, Cascino I. CTLA-4 HLA gene susceptibility to thyroid-associated orbitopathy. Lancet 1999; 354:1824.
98. Villanueva R, Inzerillo AM, Tomer Y et al. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid 2000; 10:791-8.
99. Allahabadia A, Heward JM, Nithiyananthan R, Gibson SM, Reuser TT, Dodson PM, Franklyn JA, Gough SC. MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease. Lancet 2001; 358:984-5.
100. Nithiyananthan R, Heward JM, Allahabadia A, Franklyn JA, Gough SC. Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. Thyroid 2002; 12:3-6.
101. Heward JM, Allahabadia A, Carr-Smith J et al. No evidence for allelic association of a human CTLA-4 promoter polymorphism with autoimmune thyroid disease in either population-based case-control or family-based studies. Clin Endocrinol 1998; 49:331-4.
102. Braun J, Donner H, Siegmund T, Walfish PG, Usadel KH & Badenhoop, K. CTLA-4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis. Tissue Antigens 2003; 51:563-6.
103. Vaidya B, Oakes EJ, Imrie H, Dickinson AJ, Perros P, Kendall-Taylor P, Pearce SH. CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin Endocrinol 1998; 58:732-5.